BRIEF — Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis

Oct 13 (Reuters) — NovaBridge Biosciences: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis Visara: Secures Exclusive Worldwide Rights To Develop And Commercialize Ht006.2.2 Excluding Greater China Visara: Enters Exclusive License Agreement With Wuhan Hiteck For Vis-102 Visara: Hiteck To Receive Up-front Payment, Milestone Payments, And Tiered Royalties On Net Sales Source text:... Further company coverage: NBP.O (Reuters.Briefs@thomsonreuters.com;)